Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05078047 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Study acronym: MOIO
StatusActive, Not Recruiting
PhasePhase 3
SponsorUNICANCER
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Mar 7, 2027 to May 7, 2029 Trial status: Recruiting to Active, Not Recruiting · Study sites: 40 to 33v8 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 40 to 33
  2. Primary and study completion dates: Mar 7, 2025 to Mar 7, 2027v7
  3. Study sites: 26 to 40 Eligibility criteria expanded, about 78 words · Study title shortened, about 3 wordsv6 Show 2 more changesShow less
    • Eligibility criteria expanded, about 78 words
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv5
  5. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Jun 2025 to Mar 7, 2025 · Start date changed from estimate of Jun 2022 to Mar 8, 2022 · Site details revised at 26 of 26 sitesv4 Show 3 more changesShow less
    • Primary and study completion dates: Jun 2025 to Mar 7, 2025
    • Start date changed from estimate of Jun 2022 to Mar 8, 2022
    • Site details revised at 26 of 26 sites
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Jan 2022 to Jun 2022 Primary and study completion dates: Jan 2025 to Jun 2025v3 Show 1 more changeShow less
    • Primary and study completion dates: Jan 2025 to Jun 2025
  2. Start date: Nov 2021 to Jan 2022 Primary and study completion dates: Nov 2024 to Jan 2025v2 Show 1 more changeShow less
    • Primary and study completion dates: Nov 2024 to Jan 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
UNICANCER
98 trials monitored
See 7 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
and 9 more diseases
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers. However, the optimal duration of immunotherapies is currently unknown. Our hypothesis is that a reduced dose intensity of IO could be as effective as the current standard treatment in term of prevention of the disease progression. If proved right, this study will have a positive medico-economic impact by reduction of the costs associated with the treatment and the toxicity, and an increase of the patients' quality of life.
Trial Details
NCT Number NCT05078047
Lead Sponsor UNICANCER
Conditions Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Urothelial Carcinoma +7 more
Enrollment 646 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov